Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.52 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2200367 | 0.87 | ALDH1A1 (0.62) | TP53MAPTNPC1HPGDMEN1 | |
| SCHEMBL13265968 | 0.87 | TSHR (0.62) | TP53KDM4EMAPTHPGDMEN1 | |
| SCHEMBL14537799 | 0.87 | ALDH1A1 (0.62) | TP53KDM4EMAPTPKMHPGD | |
| SCHEMBL10650255 | 0.85 | TP53 (0.61) | TP53KDM4EMAPTNPC1RAB9A | |
| SCHEMBL3197561 | 0.83 | MEN1 (0.53) | MAPTRAB9AHPGDCYP1A2MEN1 | |
| SCHEMBL1447749 | 0.82 | HPGD (0.66) | TP53KDM4EHPGDCYP1A2CYP2C9 | |
| SCHEMBL6778027 | 0.82 | HPGD (0.70) | HPGDCYP1A2CYP2C9HSD17B10GSTP1 | |
| SCHEMBL31383422 | 0.82 | CYP1A2 (0.76) | TP53HPGDCYP1A2CYP2C9HSD17B10 | |
| SCHEMBL2406839 | 0.82 | CYP1A2 (0.76) | TP53HPGDCYP1A2CYP2C9HSD17B10 | |
| Hydrochloric Acid SCHEMBL7134403 | 0.80 | HPGD (0.63) | TP53KDM4EHPGDCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099919-A1 | Composition and synthesis of new reagents for inhibition of HIV replication | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-05-03 | — | — | US | disclosed |
| EP-1119548-B1 | 3-(3-CHLORO-4-HYDROXYPHENYLAMINO)-4-(2-NITROPHENYL)-1H-PYRROLE-2,5-DIONE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITOR (GSK-3) | SMITHKLINE BEECHAM PLC (GB) | 2004-12-08 | — | — | EP | disclosed |
| US-6719520-B2 | FOR INHIBITION OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3); TREATMENT AND PROPHYLAXIS FOR DIABETES, CHRONIC NEURODEGENERATIVE CONDITIONS, MOOD DISORDERS SUCH AS SCHIZOPHRENIA AND MANIC DEPRESSION AND HAIR LOSS AND CANCER | SMITHKLINE BEECHAM CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-20040010031-A1 | Novel method and compounds | SMITHKLINE BEECHAM P.L.C. | 2004-01-15 | — | — | US | disclosed |
| WO-2001074771-A1 | PYRROLE-2,5-DIONE DERIVATIVES FOR THE TREATMENT OF DIABETES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-10-11 | — | — | WO | disclosed |
| EP-1119548-A1 | PYRROLE-2,5-DIONES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021927-A2 | PYRROLE-2,5-DIONES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010031-A1 | Novel method and compounds | GSK3A, GSK3B, GSKIP | TP53 3964/4885KDM4E 2477/4885MAPT 72/4885 |
| US-20070099919-A1 | Composition and synthesis of new reagents for inhibition of HIV replication | REV1, MAVS, ISG15 | TP53 1596/4885KDM4E 980/4885MAPT 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.